Publications by authors named "Vishwa J Amatya"

Article Synopsis
  • H3K27 trimethylation (H3K27me3), regulated by EZH2, plays a critical role in gene expression and is a key diagnostic marker for certain brain tumors, but its implications in astrocytoma with IDH mutation are unclear.
  • A study involving 33 patients analyzed the correlation between immunohistochemical markers (including H3K27me3, EZH2) and patient outcomes like overall survival (OS) and progression-free survival (PFS).
  • Results indicated that H3K27me3 positivity, particularly when combined with EZH2 positivity, was associated with poorer survival rates, suggesting it may serve as a significant prognostic factor for astrocytoma, IDH
View Article and Find Full Text PDF

Introduction: The T2-FLAIR mismatch sign is a characteristic imaging biomarker for astrocytoma, isocitrate dehydrogenase (IDH)-mutant. However, investigators have provided varying interpretations of the positivity/negativity of this sign given for individual cases the nature of qualitative visual assessment. Moreover, MR sequence parameters also influence the appearance of the T2-FLAIR mismatch sign.

View Article and Find Full Text PDF

Introduction: The WHO classification of central nervous system tumors (5th edition) classified astrocytoma, IDH-mutant accompanied with CDKN2A/B homozygous deletion as WHO grade 4. Loss of immunohistochemical (IHC) staining for methylthioadenosine phosphorylase (MTAP) was developed as a surrogate marker for CDKN2A-HD. Identification of imaging biomarkers for CDKN2A status is of immense clinical relevance.

View Article and Find Full Text PDF
Article Synopsis
  • * Researchers analyzed MRI images from 31 cases from their institution and 30 cases from The Cancer Genome Atlas, finding that the super T2-FLAIR mismatch sign is associated with significantly improved progression-free survival (PFS) and overall survival (OS).
  • * The results suggest that the super T2-FLAIR mismatch sign could serve as a valuable prognostic imaging biomarker for patients with this type of astrocytoma.
View Article and Find Full Text PDF
Article Synopsis
  • Radiation therapy (RT) can improve cancer outcomes but also increases the risk of radiation-induced brain tumors (RIBTs), which include gliomas, meningiomas, and sarcomas in survivors.
  • A comprehensive analysis of 957 patients revealed that younger patients (especially those under 5) have a higher risk for RIBTs, with median ages at irradiation being significantly lower for meningiomas compared to the other tumor types.
  • Results showed a longer latency period for meningiomas (20 years) compared to gliomas (9 years) and sarcomas (10 years), and overall survival rates were significantly better for meningioma patients versus glioma and sarcoma patients, particularly following higher radiation doses.
View Article and Find Full Text PDF

Small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) have recently been grouped as lung neuroendocrine carcinomas (NECs). Because these lung NECs are clinically malignant and their treatment strategies differ from those of non-SCLC, the quality of diagnosis has a significant prognostic impact. The diagnosis of LCNEC requires positive immunohistochemical staining with chromogranin A, synaptophysin, and CD56, along with a morphological diagnosis, and insulinoma-associated protein 1 (INSM1) has been proposed as an additional marker but is still not an ideal or better marker.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to analyze the invasiveness and recurrence rates of different subtypes of nonfunctioning pituitary neuroendocrine tumors (Pit-NETs) based on the World Health Organization's 2022 classification.
  • It included data from 292 patients who underwent transsphenoidal surgery and focused on the invasiveness of tumors to nearby structures and their recurrence rates over at least 60 months.
  • Results showed that Pit-1 lineage and null cell tumors had higher rates of cavernous sinus invasion, while recurrence rates were low overall, but tumors with cavernous sinus invasion had a higher likelihood of coming back.
View Article and Find Full Text PDF

Background/aim: Long non-coding RNAs (lncRNAs) establish gene regulatory networks in different human cancers and are involved in tumorigenesis. lncRNA LINC00152 is over-expressed in several malignant tumors and involved in tumorigenesis; however, its underlying regulatory mechanisms remain unclear. Mesothelioma, a cancer originating from mesothelial cells, is highly aggressive with a poor prognosis.

View Article and Find Full Text PDF

Epithelioid mesothelioma with a solid histologic pattern (solid epithelioid mesothelioma) is difficult to distinguish from a poorly differentiated squamous cell lung carcinoma and/or solid lung adenocarcinoma. Thus, immunohistochemical markers are essential for diagnosis; however, the sensitivity and specificity of pre-existing mesothelial markers are suboptimal, particularly for differentiation from squamous cell carcinoma. Using a cancer-dependency map, we analyzed gene expression data of pleural mesothelioma and non-small cell lung cancer cell lines (squamous cell carcinoma and adenocarcinoma) and identified secreted protein acidic and cysteine-rich (SPARC) as a promising candidate for the differential diagnosis of epithelioid mesothelioma from lung squamous cell carcinoma and/or lung adenocarcinoma.

View Article and Find Full Text PDF
Article Synopsis
  • This study investigates the effectiveness of diffusion-weighted imaging (DWI) in predicting recurrence in primary central nervous system lymphomas (PCNSLs) among patients who show a complete response (CR) after treatment.
  • The research included 54 patients divided based on the presence of residual DWI hyperintense signals, analyzing their survival outcomes, where those with residual signals had significantly shorter progression-free survival (PFS).
  • Results indicated that the R-MPV chemotherapy regimen was linked to a lower incidence of residual DWI signals, suggesting that incorporating DWI evaluation could improve treatment monitoring in PCNSL patients.
View Article and Find Full Text PDF

Background/aim: Forkhead box M1 (FOXM1) is a transcription factor closely associated with various human malignancies and is considered an attractive target for cancer therapy. Mesothelioma is a malignancy primarily due to asbestos exposure and certain genetic factors, requiring a better understanding of tumorigenesis for improved treatment. Asbestos-exposed human mesothelial cells have been reported to up-regulate FOXM1 expression in a dose-dependent manner.

View Article and Find Full Text PDF
Article Synopsis
  • Radiation-induced sarcoma (RIS) develops as a potential side effect of radiation therapy for brain tumors, with unclear clinical characteristics and treatment options.
  • The study analyzed 165 RIS cases and found an average age of 39.6 years at diagnosis, with a mean latency period of about 11.8 years and a median overall survival of 11 months, varying by type (fibrosarcoma vs. osteosarcoma) and location (intracranial vs. extracranial).
  • Surgical intervention and postoperative chemotherapy were associated with improved survival outcomes, whereas radiation treatment for RIS did not show any survival benefit.
View Article and Find Full Text PDF

Introduction: Malignant mesothelioma is an aggressive cancer associated with asbestos exposure. Currently, the efficacy of therapeutics is limited in malignant mesothelioma, and developing more effective therapies is the need of the hour. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), have attracted attention as therapeutic targets.

View Article and Find Full Text PDF

Objective: the advent of BRAF inhibitors for preoperative treatment of craniopharyngioma has necessitated the identification of BRAFV600E status. Hence, we investigated predictors of BRAFV600E mutation in craniopharyngiomas.

Methods: this retrospective study utilized data from 30 patients who were newly diagnosed with craniopharyngioma between 2011 and 2021.

View Article and Find Full Text PDF

Temozolomide is an oral alkylating agent with moderate side effects compared to other agents. However, the development of secondary malignancies following temozolomide has been reported. We describe the first case of primary central nervous system lymphoma (PCNSL) occurrence following glioblastoma treatment.

View Article and Find Full Text PDF

Introduction: The so-called radiation-induced glioma (RIG, a secondary glioma after cranial irradiation), is a serious late effect after cranial radiation therapy. The clinical characteristics of and ideal treatment for these tumors are unclear. We analyzed our case series and conducted a comprehensive literature review to reveal the precise characteristics of RIGs.

View Article and Find Full Text PDF

Pleural malignant mesothelioma is a malignant tumor with a poor prognosis that is strongly associated with asbestos exposure during its development. Because there is no adequate treatment for malignant mesothelioma, investigation of its molecular mechanism is important. The ferritin light chain (FTL) is a subunit of ferritin, and its high expression in malignant tumors, including malignant mesothelioma, has recently been reported; however, its role in malignant mesothelioma is unclear.

View Article and Find Full Text PDF

Because of nonspecific clinical and radiological findings, it is difficult to diagnose isolated neurosarcoidosis without histological examination. Distinguishing neurosarcoidosis from neoplasm, infectious disease, or granulomatous disease can be challenging. In this study, we present a case of a 61-year-old female who presented with unilateral blindness.

View Article and Find Full Text PDF

Although the routine use of immunohistochemistry has improved the accuracy of histopathologic diagnosis in clinical practice, new methods for discovering novel diagnostic markers are still needed. We sought new diagnostic markers for malignant pleural mesothelioma (MPM) using a reverse translational approach with limited archival tissues from a very rare case. Total RNA extracted from formalin-fixed paraffin-embedded (FFPE) tissues of a synchronous collision tumor consisting of MPM and pulmonary adenocarcinoma (PAC) was employed for gene expression profiling (GEP) analysis.

View Article and Find Full Text PDF

Malignant mesothelioma is a tumor with a poor prognosis, mainly caused by asbestos exposure and with no adequate treatment yet. To develop future therapeutic targets, we analyzed the microarray dataset GSE 29370 of malignant mesothelioma and reactive mesothelial hyperplasia, downloaded from the Gene Expression Omnibus (GEO) database. We identified insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) as one of the significantly upregulated genes in malignant mesothelioma.

View Article and Find Full Text PDF

Double pituitary adenomas (DPAs), especially metachronous DPAs, are extremely rare and there has been no report about DPAs with altered transcriptional factors. We describe the case of a 25-year-old man who presented with acromegaly 7 years after surgery for a non-functioning pituitary adenoma (NFPA). Before the initial surgery, endocrine evaluation confirmed NFPA or silent somatotroph pituitary adenoma (SPA) because of normal serum levels of insulin-like growth factor-1 (IGF-1) and insufficient suppression of growth hormone (GH) levels in the oral glucose tolerance test (OGTT).

View Article and Find Full Text PDF

Background: Diffuse midline glioma (DMG), H3 K27M-mutant including diffuse intrinsic pontine glioma (DIPG) is a disease with dismal prognosis. We focused on diffusion-weighted imaging (DWI) and gadolinium enhanced T1WI (Gd), especially high intensity on DWI at non-enhanced lesion, i.e.

View Article and Find Full Text PDF

Malignant mesothelioma is a highly aggressive tumor, and an effective strategy for its treatment is not yet available. Long non‑coding RNAs (lncRNAs) have been reported to be associated with various biological processes, including the regulation of gene expression of cancer‑related pathways. Among various lncRNAs, plasmacytoma variant translocation 1 () acts as a tumor promoter in several human cancers, but its mechanism of action has not yet been elucidated.

View Article and Find Full Text PDF